Alla studier
RekryteringPHASE2, PHASE3INTERVENTIONELL

Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy

This research study is investigating a new medicine called Tideglusib for individuals aged 6 to 45 who have a muscle condition known as Congenital or Childhood Onset Myotonic Dystrophy (DM1). This condition is present from birth or develops in childhood. The main goals of the study are to understand how safe the medicine is and how well it works. Some participants will have taken part in a previous study with this medicine, while others will be trying it for the first time. Participants will receive the medicine for about a year, with the possibility of taking it for longer. This study is an important step in finding better ways to help people living with DM1.

Överblick

Status
Rekrytering
Fas
PHASE2, PHASE3
Sponsor
AMO Pharma Limited
Inskrivningsmål
76
Starta
23 Aug 2021
Beräknad slutförande
31 dec 2026

Vad handlar denna studie om?

This study is all about a medicine called Tideglusib and how it might help children and young people who have a muscle condition called Myotonic Dystrophy type 1 (DM1). Specifically, it's for those who were born with the condition (Congenital DM1) or developed it in childhood (Childhood Onset DM1). Myotonic Dystrophy causes muscles to become weak and tight, and it can affect different parts of the body.

The researchers want to learn two main things: first, how safe Tideglusib is for people with DM1, and second, how well it works to reduce the symptoms of the condition. Finding new and effective treatments is really important for improving the lives of individuals with DM1. This study is an 'open-label' study, which means everyone involved, including the participants and the doctors, will know that Tideglusib is being given.

Participants will take Tideglusib for about a year, and there might be an option to continue taking it for longer after that. The amount of medicine given will depend on the person's weight. Some people in this study will have already been part of a previous study testing Tideglusib, while others will be trying it for the first time. This blend of participants helps researchers gather a lot of information about the medicine.

Viktiga punkter

  • This study is testing a new medicine called Tideglusib for Congenital or Childhood Myotonic Dystrophy (DM1).
  • It's for people aged 6 to 45 with a confirmed DM1 diagnosis.
  • Participants will take the medicine daily for about a year, with regular check-ups.
  • The study aims to understand the medicine's safety and how well it works.
  • You'll know you are receiving the active medicine (Tideglusib).
  • Deltagande är frivilligt, och du kan dra dig ur när som helst.

Vem kan vara berättigad?

To join this study, participants generally need to be diagnosed with Congenital or Childhood Onset Myotonic Dystrophy (DM1), and this diagnosis must be confirmed by a genetic test. They need to be between 6 and 45 years old when the study starts. Also, a doctor needs to assess their DM1 symptoms and confirm they are at a certain level of severity.

If you haven't been in the previous study (AMO-02-MD-2-003) but are interested, you'll need to meet all these criteria. For all participants, a parent or legal guardian must agree to you joining the study, and if you're old enough, you'll also need to agree. Your caregiver must be able to support you throughout the study, and you must be willing to follow any special food instructions.

There are also a few reasons why someone might not be able to join. For example, if your body mass index (a measure of weight compared to height) is too low (under 13.5) or too high (over 40). Also, if you've recently started or changed certain medications or therapies, you might not be able to take part.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Do I have a confirmed genetic diagnosis of Congenital or Childhood Myotonic Dystrophy (DM1)?
  2. Am I between 6 and 45 years old?
  3. Am I able to commit to regular clinic visits and follow study instructions?
  4. Is my caregiver willing and able to support my participation throughout the study?
  5. Do I have a body mass index (BMI) within the healthy range (not too low or too high)?
  6. Have I recently started or changed other treatments, which might prevent me from joining?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to take part in this study, you will be taking a medicine called Tideglusib daily for about 52 weeks (roughly one year). The amount of medicine you receive will be carefully measured based on your weight. After this main treatment period, there's a chance you could continue taking the medicine for an extended time if the study allows.

Throughout the study, you'll have regular visits to the clinic so the doctors can check on your health and how the medicine is affecting you. These visits might include physical examinations, blood tests, and assessments of your muscle strength and daily activities. Your caregiver will need to help you attend these appointments and follow the study instructions, including any special rules about what you can eat.

Before you start, you'll have a screening visit to make sure you're a good fit for the study. The total time you're involved could be over a year, depending on whether you join the extended treatment period.

Potentiella risker och fördelar

Taking part in any medical study has potential benefits and risks. A potential benefit of this study is that Tideglusib might improve the symptoms of Myotonic Dystrophy, which could lead to a better quality of life. However, it's important to remember that this medicine is still being tested, and we don't yet know for sure how effective it will be for everyone, or if it will have any benefits at all. On the other hand, there might be side effects from taking Tideglusib, although the study is designed to carefully monitor for any problems. You will be told about all known potential risks before you decide to join. Remember, taking part is completely voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Platser (14)

  • Arkansas Children's Hospital
    Verifierat postnummer
    Little Rock, USA· Rekrytering
  • University of California, Los Angeles (UCLA)
    Verifierat postnummer
    Los Angeles, USA· Registrering genom inbjudan
  • Stanford Universitet
    Verifierat postnummer
    Palo Alto, USA· Registrering genom inbjudan
  • Lurie's Children's Hospital
    Verifierat postnummer
    Chicago, USA· Rekrytering
  • Universitetssjukhuset i Iowa
    Verifierat postnummer
    Iowa City, USA· Rekrytering
  • University of Rochester - Medical Center
    Verifierat postnummer
    Rochester, USA· Rekrytering
  • University of Pittsburgh Medical Center
    Verifierat postnummer
    Pittsburgh, USA· Rekrytering
  • University of Utah Clinical Neurosciences Center
    Verifierat postnummer
    Salt Lake City, USA· Rekrytering
  • Children's Hospital of The King's Daughters
    Verifierat postnummer
    Norfolk, USA· Återkallad
  • Virginia Commonwealth University-Department of Neurology - Muscular Dystrophy Translational Research Program
    Verifierat postnummer
    Richmond, USA· Avslutad
  • The Bright Alliance
    Verifierat postnummer
    Randwick, Australien· Rekrytering
  • Children's Hospital London Health Sciences Centre (LHSC)
    Verifierat postnummer
    London, Kanada· Registrering genom inbjudan

Vanliga frågor

What is Myotonic Dystrophy (DM1)?

Myotonic Dystrophy type 1 (DM1) is a genetic condition that mainly causes muscle weakness and difficulty relaxing muscles. It can develop from birth (Congenital) or childhood.

What is Tideglusib?

Tideglusib is a new medicine being studied to see if it can help people with Myotonic Dystrophy. It's not yet approved for general use.

Kommer jag att veta om jag får den riktiga medicinen?

Yes, this is an 'open-label' study, which means everyone involved will know that participants are receiving Tideglusib.

How long will I be taking the medicine?

You will take the medicine for about 52 weeks (one year), with a possibility of continuing for longer if you wish and if the study allows.

Vad händer om jag ändrar mig efter att jag har gått med?

You can leave the study at any time, for any reason, without it affecting your usual medical care.

Hur du får reda på mer

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "Safety and Efficacy of Tideglusib in Congenital or Childhood…" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.